151 related articles for article (PubMed ID: 9297070)
1. [Economic aspects of drug therapy exemplified by pravastatin. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart disease patients].
Berger K; Klose G; Szucs TD
Med Klin (Munich); 1997 Jun; 92(6):363-9. PubMed ID: 9297070
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study].
Szucs TD; Guggenberger G; Berger K; März W; Schäfer JR
Herz; 1998 Aug; 23(5):319-29. PubMed ID: 9757381
[TBL] [Abstract][Full Text] [Related]
3. [Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial].
Szucs TD; Berger K; März W; Schäfer JR
Herz; 2000 Aug; 25(5):487-94. PubMed ID: 10992997
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model.
Muls E; Van Ganse E; Closon MC
Atherosclerosis; 1998 Apr; 137 Suppl():S111-6. PubMed ID: 9694550
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
Tonkin AM; Eckermann S; White H; Friedlander D; Glasziou P; Magnus P; Kirby A; Mulray S; Denton M; Sallaberger M; Hunt D; Simes J;
Am Heart J; 2006 Jun; 151(6):1305-12. PubMed ID: 16781242
[TBL] [Abstract][Full Text] [Related]
6. Design of a cost-effectiveness study within a randomized trial: the LIPID Trial for Secondary Prevention of IHD. Long-term Intervention with Pravastatin in Ischemic Heart disease.
Glasziou PP; Simes RJ; Hall J; Donaldson C
Control Clin Trials; 1997 Oct; 18(5):464-76. PubMed ID: 9315428
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID Study].
Szucs TD; Bertel O; Darioli R; Gutzwiller F; Mordasini R
Praxis (Bern 1994); 2000 Apr; 89(18):745-52. PubMed ID: 10823012
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?
Glasziou PP; Eckermann SD; Mulray SE; Simes RJ; Martin AJ; Kirby AC; Hall JP; Caleo S; White HD; Tonkin AM
Med J Aust; 2002 Oct; 177(8):428-34. PubMed ID: 12381252
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacoeconomic analysis of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy for the secondary prevention of coronary heart disease].
Sato S; Matsushita Y; Kobayashi T; Awata N
Nihon Eiseigaku Zasshi; 2004 Jul; 59(3):335-41. PubMed ID: 15359898
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.
Ashraf T; Hay JW; Pitt B; Wittels E; Crouse J; Davidson M; Furberg CD; Radican L
Am J Cardiol; 1996 Aug; 78(4):409-14. PubMed ID: 8752184
[TBL] [Abstract][Full Text] [Related]
11. [Cost-benefit analysis of an evidence-based secondary prevention of coronary heart diseases by statins. An analysis for Germany from a social security perspective].
Klever-Deichert G; Hinzpeter B; Wendland G; Lauterbach K
Med Klin (Munich); 2000 Jun; 95(6):305-13. PubMed ID: 10935414
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of coronary prevention.
Szucs TD; März W
Eur Heart J; 1999 Feb; 20(4):317-8. PubMed ID: 10099929
[No Abstract] [Full Text] [Related]
13. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy.
Morris S
Health Econ; 1997; 6(6):589-601. PubMed ID: 9466141
[TBL] [Abstract][Full Text] [Related]
14. Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial.
Avorn J; Benner J; Ford I; Ganz DA; Gaw A; Glynn RJ; Jackson J; Lagaay AM; Schneeweiss S; Walley T; Wang PS;
Control Clin Trials; 2002 Dec; 23(6):757-73. PubMed ID: 12505250
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.
Tsevat J; Kuntz KM; Orav EJ; Weinstein MC; Sacks FM; Goldman L
Am Heart J; 2001 May; 141(5):727-34. PubMed ID: 11320359
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.
Pharoah PD; Hollingworth W
BMJ; 1996 Jun; 312(7044):1443-8. PubMed ID: 8664620
[TBL] [Abstract][Full Text] [Related]
19. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
Coukell AJ; Wilde MI
Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of statins.
Huse DM; Russell MW; Miller JD; Kraemer DF; D'Agostino RB; Ellison RC; Hartz SC
Am J Cardiol; 1998 Dec; 82(11):1357-63. PubMed ID: 9856919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
